SAN DIEGO, CA / ACCESSWIRE / May 2, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in shares of Edge Therapeutics, Inc. (NASDAQ: EDGE).
Investors who purchased shares of Edge Therapeutics, Inc. (NASDAQ: EDGE) have certain options and for certain investors are short and strict deadlines running. NASDAQ: EDGE investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On March 28, 2018, Edge Therapeutics disclosed, "that a pre-specified interim analysis on data from the Day 90 visit of the first 210 subjects randomized and treated in the Phase 3 NEWTON 2 study of EG-1962 demonstrated a low probability of achieving a statistically-significant difference compared to the standard of care in the study's primary endpoint, if the study is fully enrolled." As a result, the Data Monitoring Committee "recommended that the study be stopped based on its conclusion that the study has a low probability of meeting its primary endpoint." Based on the DMC recommendation, Edge Therapeutics stated that it has decided to discontinue the Phase 3 NEWTON 2 study.
On April 23, 2018, a lawsuit was filed against Edge Therapeutics, Inc. over alleged securities laws violations. The plaintiff claims that the defendants failed to disclose that the Company's lead product candidate EG-1962 would likely fail a futility analysis in connection with the NEWTON 2 study, and that, as a result of the foregoing, the Company's financial statements and Defendants' statements about Edge's business, operations, and prospects, were materially false and misleading at all relevant times.
Those who purchased Edge Therapeutics, Inc. (NASDAQ: EDGE) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
SOURCE: Shareholders Foundation, Inc.
